Danaher Corporation ranks third among the 10 Best Investments During A Recession. TD Cowen raised DHR’s price target to $270 from $260, maintaining a Buy rating, citing potential upside for the company in 2026. DHR expects adjusted EPS between $7.70 and $7.80 for 2025 and mid-single-digit sales growth for Q4.

Danaher Corporation is a global science and technology innovator with a focus on Life Sciences and Diagnostics. The company offers tools and services that enhance patient health and support the development of life-changing therapies. Analysts see DHR as a strong investment, but suggest AI stocks may have greater upside potential with less risk.

For more investment opportunities, check out the 12 Best Multibagger Stocks to Buy Heading into 2026 and the 7 Best Rising Tech Stocks to Buy Now. Consider exploring a free report on the best short-term AI stock for potential investment options. No disclosures were provided in the article.

Read more at Yahoo Finance: Danaher Corporation (DHR) Maintains Buy Rating as Analysts See Upside in 2026